Literature DB >> 29314143

Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.

Radboud J Duintjer Tebbens1, Mark A Pallansch2, Stephen L Cochi3, Derek T Ehrhardt3, Noha H Farag3, Stephen C Hadler3, Lee M Hampton3, Maureen Martinez3, Steve G F Wassilak3, Kimberly M Thompson1.   

Abstract

Due to security, access, and programmatic challenges in areas of Pakistan and Afghanistan, both countries continue to sustain indigenous wild poliovirus (WPV) transmission and threaten the success of global polio eradication and oral poliovirus vaccine (OPV) cessation. We fitted an existing differential-equation-based poliovirus transmission and OPV evolution model to Pakistan and Afghanistan using four subpopulations to characterize the well-vaccinated and undervaccinated subpopulations in each country. We explored retrospective and prospective scenarios for using inactivated poliovirus vaccine (IPV) in routine immunization or supplemental immunization activities (SIAs). The undervaccinated subpopulations sustain the circulation of serotype 1 WPV and serotype 2 circulating vaccine-derived poliovirus. We find a moderate impact of past IPV use on polio incidence and population immunity to transmission mainly due to (1) the boosting effect of IPV for individuals with preexisting immunity from a live poliovirus infection and (2) the effect of IPV-only on oropharyngeal transmission for individuals without preexisting immunity from a live poliovirus infection. Future IPV use may similarly yield moderate benefits, particularly if access to undervaccinated subpopulations dramatically improves. However, OPV provides a much greater impact on transmission and the incremental benefit of IPV in addition to OPV remains limited. This study suggests that despite the moderate effect of using IPV in SIAs, using OPV in SIAs remains the most effective means to stop transmission, while limited IPV resources should prioritize IPV use in routine immunization.
© 2018 Society for Risk Analysis.

Entities:  

Keywords:  Dynamic modeling; polio eradication; risk management

Mesh:

Substances:

Year:  2018        PMID: 29314143      PMCID: PMC7879700          DOI: 10.1111/risa.12962

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  40 in total

1.  Progress toward poliomyelitis eradication--Pakistan, 1994-1998.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-02-19       Impact factor: 17.586

Review 2.  Expert review on poliovirus immunity and transmission.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Konstantin M Chumakov; Neal A Halsey; Tapani Hovi; Philip D Minor; John F Modlin; Peter A Patriarca; Roland W Sutter; Peter F Wright; Steven G F Wassilak; Stephen L Cochi; Jong-Hoon Kim; Kimberly M Thompson
Journal:  Risk Anal       Date:  2012-07-15       Impact factor: 4.000

3.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

4.  Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.

Authors:  Dominika A Kalkowska; Radboud J Duintjer Tebbens; Itamar Grotto; Lester M Shulman; Emilia Anis; Steven G F Wassilak; Mark A Pallansch; Kimberly M Thompson
Journal:  J Infect Dis       Date:  2014-12-10       Impact factor: 5.226

5.  Progress and peril: poliomyelitis eradication efforts in Pakistan, 1994-2013.

Authors:  James P Alexander; Mufti Zubair; Muzaffar Khan; Nima Abid; Elias Durry
Journal:  J Infect Dis       Date:  2014-11-01       Impact factor: 5.226

6.  The role of older children and adults in wild poliovirus transmission.

Authors:  Isobel M Blake; Rebecca Martin; Ajay Goel; Nino Khetsuriani; Johannes Everts; Christopher Wolff; Steven Wassilak; R Bruce Aylward; Nicholas C Grassly
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

7.  Quantifying the impact of expanded age group campaigns for polio eradication.

Authors:  Bradley G Wagner; Matthew R Behrend; Daniel J Klein; Alexander M Upfill-Brown; Philip A Eckhoff; Hao Hu
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

8.  Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.

Authors:  Jacob John; Sidhartha Giri; Arun S Karthikeyan; Miren Iturriza-Gomara; Jayaprakash Muliyil; Asha Abraham; Nicholas C Grassly; Gagandeep Kang
Journal:  Lancet       Date:  2014-07-10       Impact factor: 79.321

9.  Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2015-09-17       Impact factor: 3.090

10.  Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2016-03-24       Impact factor: 3.090

View more
  12 in total

1.  Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  Risk Anal       Date:  2018-09-21       Impact factor: 4.000

2.  Environmental Surveillance System Characteristics and Impacts on Confidence About No Undetected Serotype 1 Wild Poliovirus Circulation.

Authors:  Dominika A Kalkowska; Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  Risk Anal       Date:  2018-09-21       Impact factor: 4.000

3.  Effect of Population Partitioning on the Probability of Silent Circulation of Poliovirus.

Authors:  Celeste Vallejo; Carl A B Pearson; James S Koopman; Thomas J Hladish
Journal:  Bull Math Biol       Date:  2022-05-04       Impact factor: 3.871

4.  Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Pakistan and Afghanistan.

Authors:  Dominika A Kalkowska; Radboud J Duintjer Tebbens; Mark A Pallansch; Kimberly M Thompson
Journal:  Risk Anal       Date:  2018-10-08       Impact factor: 4.000

5.  Poliovirus immunity among children under five years-old in accessible areas of Afghanistan, 2013.

Authors:  Christopher H Hsu; Kathleen A Wannemuehler; Sajid Soofi; Mohd Mashal; Imtiaz Hussain; Zulfiqar A Bhutta; Larin McDuffie; William Weldon; Noha H Farag
Journal:  Vaccine       Date:  2019-02-16       Impact factor: 3.641

6.  Poliovirus containment risks and their management.

Authors:  Radboud J Duintjer Tebbens; Dominika A Kalkowsa; Kimberly M Thompson
Journal:  Future Virol       Date:  2018-08-10       Impact factor: 1.831

Review 7.  Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  Expert Rev Vaccines       Date:  2018-08-09       Impact factor: 5.217

8.  Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan.

Authors:  Dominika A Kalkowska; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-03-06       Impact factor: 4.000

9.  Modeling Poliovirus Surveillance and Immunization Campaign Quality Monitoring Costs for Pakistan and Afghanistan for 2019-2023.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Stephen L Cochi; Kimberly M Thompson
Journal:  Open Forum Infect Dis       Date:  2021-05-23       Impact factor: 3.835

Review 10.  Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Risk Anal       Date:  2020-04-27       Impact factor: 4.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.